Online citations, reference lists, and bibliographies.
← Back to Search

Megakaryocyte Potentiation Factor Cleaved From Mesothelin Precursor Is A Useful Tumor Marker In The Serum Of Patients With Mesothelioma

M. Onda, Satoshi Nagata, M. Ho, T. Bera, R. Hassan, R. Alexander, I. Pastan
Published 2006 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose: To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma. Experimental Design: Mice were immunized with a purified recombinant human MPF-rabbit-Fc fusion protein and with MPF. Several hybridomas producing mAbs to MPF were established. A double-determinant (sandwich) ELISA was constructed using mAbs to two different epitopes and used to determine if MPF is present in the serum of patients with mesothelioma. Results: We established seven anti-MPF mAbs whose topographical epitopes were classified into three nonoverlapping groups. All the mAbs reacted with recombinant MPF protein by ELISA. One of the mAbs detected MPF and the mesothelin precursor protein containing MPF in cell lysates on Western blotting. A sandwich ELISA using mAbs to two different epitopes was constructed and used to measure the presence of MPF in the media of various mesothelin-expressing cancer cell lines and in human serum. The ELISA showed that MPF levels were elevated in 91% (51 of 56) of patients with mesothelioma compared with healthy controls. Furthermore, serum MPF fell to normal levels in two patients after surgery for their peritoneal mesothelioma. Conclusions: Using new mAbs to MPF, we showed that MPF is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma. Measurement of MPF may be useful in following the response of mesothelioma to treatment.
This paper references
10.1158/1078-0432.CCR-05-0578
New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA
M. Onda (2005)
A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5.
N. Yamaguchi (1994)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
Indications for pneumonectomy . Extrap - leural pneumonectomy
RuschVW (1999)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
P. Argani (2001)
10.1016/J.JIM.2004.06.009
Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay.
Satoshi Nagata (2004)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intra peritoneal chemotherapy
A L Feldman (2003)
American Association for Cancer clincancerres.aacrjournals.org Downloaded from
(2006)
10.1097/01.blo.0000137544.30200.b6
TP-3 Immunotoxins Improve Antitumor Activity in Mice with Osteosarcoma
M. Onda (2005)
10.1002/AJIM.20246
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
Takehiko Murayama (2006)
Glycosylphosphatidylinosi - tolanchored proteins : structure , function , and cleavage by phosphatidylinositolspecific phospholipase C
FJ Sharon (2002)
10.1128/MCB.20.8.2902-2906.2000
Mesothelin Is Not Required for Normal Mouse Development or Reproduction
T. Bera (2000)
10.1200/JCO.2003.04.150
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
A. Feldman (2003)
10.1097/01.pai.00000141545.36485.d6
Localization of Mesothelin in Epithelial Ovarian Cancer
R. Hassan (2005)
10.1084/jem.20031435
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
A. M. Thomas (2004)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1074/jbc.M312372200
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion*
A. Rump (2004)
10.1139/O02-146
Glycosylphosphatidylinositol-anchored proteins: structure, function, and cleavage by phosphatidylinositol-specific phospholipase C.
F. Sharom (2002)
10.1158/1078-0432.CCR-04-2304
Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients
M. Ho (2005)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1016/S0022-1759(03)00192-3
DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins.
Satoshi Nagata (2003)
Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
M. Onda (2001)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
10.1309/F1B64CL7H8VJKEAF
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
R. Hassan (2005)
10.1074/jbc.270.37.21984
Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*)
T. Kojima (1995)
Glycosylphosphatidylinosi - tol - anchored proteins : structure , function , and cleavage by phosphatidylinositol - specific phospholipase C
FJ Sharon (2002)
10.1006/SMIM.1994.1012
How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membrane.
P. Censullo (1994)
10.1002/IJC.2910500308
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium
K. Chang (1992)
Indications for pneumonectomy. Extrapleural pneumonectomy.
V. Rusch (1999)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1136/oem.2003.010165
Changing trends in US mesothelioma incidence
H. Weill (2004)
Indications for pneumonectomy
Uglov Fg (1948)
Megakaryocyte Potentiation Factor as aTumor Marker www
(2006)
10.1002/AJIM.10047
Malignant mesothelioma in Australia, 1945-2000.
J. Leigh (2002)
Immunohistochemical diagnosis of mesothelioma
J. Legier (1994)
Malignant mesothelioma in Australia
A. Musk (2006)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)



This paper is referenced by
10.1200/PO.17.00282
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma.
L. Cao (2018)
10.1007/978-3-030-16884-1_3
Screening Issues in Exposed Subjects and Early Diagnosis
M. Mencoboni (2019)
10.3892/OR_00000155
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
K. Inami (2008)
10.4172/2153-0602.S2-001
Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos
Hidenori Matsuzaki (2013)
10.2174/9781681081946116010023
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
Tommaso Claudio Mineo and Vincenzo Ambrogi (2016)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1371/journal.pone.0104388
Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
J. Zhang (2014)
10.1016/j.taap.2010.09.026
Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs.
A. Takata (2011)
10.1016/j.bbrc.2008.02.114
MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
T. Segawa (2008)
10.1080/15287394.2012.641203
Long-Term Response of Rats to Single Intratracheal Exposure of Libby Amphibole or Amosite
J. M. Cyphert (2012)
An Update on Biomarkers and Treatment
Mandira Ray (2015)
10.1111/j.1349-7006.2007.00520.x
Diagnostic biomarker of asbestos‐related mesothelioma: Example of translational research
Hino Okio (2007)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1097/CPM.0b013e318272ce61
Mesothelioma: Update on Diagnostic Strategies
Carmen M. Rosario (2012)
10.1038/leu.2016.218
RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY
J. Khorashad (2016)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1186/1472-6807-9-1
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
B. K. Sathyanarayana (2008)
10.1016/S0761-8425(07)78148-2
Mésothéliome pleural : conséquences de la stadification sur la stratégie thérapeutique
L. Greillier (2007)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
- 1-Comparisons and combinations of the five tumor markers for mesothelioma : NERC / mesothelin , osteopontin , hyaluronic acid , CA 125 , and CYFRA 21-1
K. Shiomi (2011)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.1159/000100446
Blood Tests for Asbestos-Related Mesothelioma
M. Maeda (2006)
10.1111/j.1349-7006.2007.00438.x
Establishment of the enzyme‐linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin
M. Nakaishi (2007)
10.1007/s12199-007-0014-9
Diagnostic tumor marker of asbestos-related mesothelioma
O. Hino (2008)
A Comparison of Diffe rent Treatments for Mesothelioma
Samira Rezaei (2014)
10.1158/0008-5472.CAN-14-0337
Discovery of mesothelin and exploiting it as a target for immunotherapy.
I. Pastan (2014)
10.4081/MONALDI.2009.374
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
B. Grigoriu (2009)
highlights several prognostic biomarkers for malignant mesothelioma.
Filip Mundt (2013)
10.1186/1750-1172-3-34
Malignant mesothelioma
A. Moore (2008)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1369/jhc.2008.950477
Mesothelin Expression in the Leptomeninges and Meningiomas
M. Johnson (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar